{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:24:21Z","timestamp":1791973461300,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CAR-T\u00a0cell (chimeric antigen receptor\u00a0T) therapy is now part of standard of care treatment of B\u2011cell lineage malignancies. Although it is an effective treatment, it comes along with adverse side effects and toxicities that may require intensive care therapy. The costs related to critical care therapy in critically ill patients after CAR\u2011T administration have not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Retrospective analysis of all patients who had received CAR\u2011T therapy and were admitted to the intensive care unit (ICU) of a\u00a0tertiary care university medical centre in Germany between 1\u00a0January\u00a02019 and 31\u00a0December\u00a02022. Cause of admission and ICU therapy as well as treatment and total hospitals costs were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty patients with a\u00a0history of CAR-T\u00a0cell therapy for underlying haematological malignancy were included. The median age of all patients was 60\u00a0years (interquartile range [IQR] 50\u201370) and 37% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u200911) were female. 93% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u200928) of patients had non-Hodgkin lymphoma and 7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u20092) had multiple myeloma. The cohort was stratified whether the ICU admission was CAR\u2011T therapy related (i.e. within 30\u00a0days after CAR\u2011T therapy; 73%,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u200922) or the admission was of an other cause (&gt; 30\u00a0days after CAR\u2011T therapy) (27%,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u20098). The median duration from CAR\u2011T therapy to ICU admission was 6 (range 5\u20138)\u00a0days in CAR-T\u00a0cell therapy associated ICU admissions compared with 52 (range 31\u2013126)\u00a0days in other admissions. The overall illness severity on admission was numerically higher in CAR-T-related ICU admission compared to other admissions (46 vs.\u00a043\u00a0points,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.18). Vasopressor therapy (50% vs.\u00a075%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.19), invasive mechanical ventilation (27% vs.\u00a050%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.24) and renal replacement therapy (14% vs.\u00a050%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.05) were used in CAR-T-associated admission compared to other admissions, respectively. The ICU mortality (23% vs.\u00a050%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.15) was higher in patients with other ICU admission. Median total costs of the entire inpatient stay in hospital were \u20ac\u202f27,845 (range 8661\u2013368,286\u202f\u20ac) in CAR-T-associated ICU admissions compared to \u20ac\u202f59,234 (range 23,182\u2013127,044\u202f\u20ac) in the group of other ICU admissions (costs of the CAR\u2011T product not included).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In relation to the total costs of CAR-T-cell therapy (production of the CAR\u2011T product), therapy-associated complications have a\u00a0relatively low impact on the costs and utilization of ICU resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00063-024-01230-z","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:39:29Z","timestamp":1735544369000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of critically ill adult CAR-T\u00a0cell recipients\u2014analysis from a\u00a0healthcare payer perspective","Wirtschaftliche Bewertung von erwachsenen CAR-T-Zellen-Empf\u00e4ngern in kritischem Zustand \u2013 eine Analyse aus der Sicht eines Kostentr\u00e4gers im Gesundheitswesen"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0721-9027","authenticated-orcid":false,"given":"Kevin","family":"Roedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paymon","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Haar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"5","key":"1230_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude\u00a0SL, Laetsch\u00a0TW, Buechner\u00a0J, Rives\u00a0S, Boyer\u00a0M, Bittencourt\u00a0H et\u00a0al (2018) Tisagenlecleucel in children and young adults with B\u2011cell lymphoblastic leukemia. N\u00a0Engl J Med 378(5):439\u2013448","journal-title":"N Engl J Med"},{"issue":"26","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu\u00a0SS, Locke\u00a0FL, Bartlett\u00a0NL, Lekakis\u00a0LJ, Miklos\u00a0DB, Jacobson\u00a0CA et\u00a0al (2017) Axicabtagene Ciloleucel CAR T\u2011Cell Therapy in Refractory Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"1","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS, Waller\u00a0EK, Borchmann\u00a0P, McGuirk\u00a0JP et\u00a0al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"9","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann\u00a0J, Sch\u00fc\u00dfler-Lenz\u00a0M, Bondanza\u00a0A, Buchholz\u00a0CJ (2017) Clinical development of CAR T\u00a0cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 9(9):1183\u20131197","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1164\/rccm.201810-1945ED","volume":"200","author":"E Azoulay","year":"2019","unstructured":"Azoulay\u00a0E, Shimabukuro-Vornhagen\u00a0A, Darmon\u00a0M, von Bergwelt-Baildon\u00a0M (2019) Critical Care Management of Chimeric Antigen Receptor T\u00a0Cell-related Toxicity. Be Aware and Prepared. Am J Respir Crit Care Med 200(1):20\u201323","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","volume":"8","author":"\u00c9 Azoulay","year":"2021","unstructured":"Azoulay \u00c9, Castro\u00a0P, Maamar\u00a0A, Metaxa\u00a0V, de Moraes\u00a0AG, Voigt\u00a0L et\u00a0al (2021) Outcomes in patients treated with chimeric antigen receptor T\u2011cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol 8(5):e355\u2013e64","journal-title":"Lancet Haematol"},{"key":"1230_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","volume":"58","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez\u00a0C, Brown\u00a0ART, Herr\u00a0MM, Kadri\u00a0SS, Hill\u00a0B, Rajendram\u00a0P et\u00a0al (2020) The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T\u2011cell associated toxicities. J\u00a0Crit Care 58:58\u201364","journal-title":"J Crit Care"},{"issue":"1","key":"1230_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2019.05.005","volume":"13","author":"JC Chavez","year":"2020","unstructured":"Chavez\u00a0JC, Jain\u00a0MD, Kharfan-Dabaja\u00a0MA (2020) Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T\u2011cell therapy: A\u00a0comprehensive review of emerging grading models. Hematol Oncol Stem Cell Ther 13(1):1\u20136","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay\u00a0KA (2018) Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T\u00a0cell therapy. Br J Haematol 183(3):364\u2013374","journal-title":"Br J Haematol"},{"key":"1230_CR10","unstructured":"Garcia Borrega J, Heindel K, Goreci Y, Warnke C, Onur OA, Kochanek M et\u00a0al (2021) Toxicity after chimeric antigen receptor T\u2011cell therapy : Overview and management of early and late onset side effects. Internist (berl)"},{"issue":"1","key":"1230_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","volume":"12","author":"S Valade","year":"2022","unstructured":"Valade\u00a0S, Darmon\u00a0M, Zafrani\u00a0L, Mariotte\u00a0E, Lemiale\u00a0V, Bredin\u00a0S et\u00a0al (2022) The use of ICU resources in CAR-T\u00a0cell recipients: a\u00a0hospital-wide study. Ann Intensive Care 12(1):75","journal-title":"Ann Intensive Care"},{"key":"1230_CR12","doi-asserted-by":"publisher","first-page":"154511","DOI":"10.1016\/j.jcrc.2023.154511","volume":"80","author":"L Scourfield","year":"2024","unstructured":"Scourfield\u00a0L, Pirani\u00a0T, Singh\u00a0N, Saha\u00a0R, Kuhnl\u00a0A, Sanderson\u00a0R et\u00a0al (2024) An update on ICU outcomes in patients after CAR T therapy: A\u00a0four-year tertiary UK centre experience. J\u00a0Crit Care 80:154511","journal-title":"J Crit Care"},{"issue":"12","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust\u00a0J, Taraseviciute\u00a0A, Turtle\u00a0CJ (2018) Neurotoxicity Associated with CD19-Targeted CAR-T\u00a0Cell Therapies. Cns Drugs 32(12):1091\u20131101","journal-title":"Cns Drugs"},{"issue":"1","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill\u00a0JA, Li\u00a0D, Hay\u00a0KA, Green\u00a0ML, Cherian\u00a0S, Chen\u00a0X et\u00a0al (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T\u2011cell immunotherapy. Blood 131(1):121\u2013130","journal-title":"Blood"},{"issue":"12","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"e0278950","DOI":"10.1371\/journal.pone.0278950","volume":"17","author":"S Chacim","year":"2022","unstructured":"Chacim\u00a0S, Monjardino\u00a0T, Cunha\u00a0JL, Medeiros\u00a0P, Redondo\u00a0P, Bento\u00a0MJ et\u00a0al (2022) Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T\u2011cell therapy: Results from a\u00a0comprehensive cancer center. PLoS ONE 17(12):e278950","journal-title":"PLoS ONE"},{"issue":"7","key":"1230_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent\u00a0JL, Moreno\u00a0R, Takala\u00a0J, Willatts\u00a0S, De Mendonca\u00a0A, Bruining\u00a0H et\u00a0al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707\u2013710","journal-title":"Intensive Care Med"},{"issue":"24","key":"1230_CR17","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall\u00a0JR, Lemeshow\u00a0S, Saulnier\u00a0F (1993) A\u00a0new Simplified Acute Physiology Score (SAPS II) based on a\u00a0European\/North American multicenter study. JAMA 270(24):2957\u20132963","journal-title":"JAMA"},{"issue":"5","key":"1230_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson\u00a0ME, Pompei\u00a0P, Ales\u00a0KL, MacKenzie\u00a0CR (1987) A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J\u00a0Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"8","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer\u00a0M, Deutschman\u00a0CS, Seymour\u00a0CW, Shankar-Hari\u00a0M, Annane\u00a0D, Bauer\u00a0M et\u00a0al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):801\u2013810","journal-title":"JAMA"},{"issue":"4","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL, Ghobadi\u00a0A, Turtle\u00a0CJ, Brudno\u00a0JN et\u00a0al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"1230_CR21","unstructured":"(2023) https:\/\/www.vdek.com\/vertragspartner\/Krankenhaeuser\/landesbasisfallwerte.html"},{"key":"1230_CR22","unstructured":"In E (2023) http:\/\/g-drg.de\/cms\/"},{"issue":"6","key":"1230_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/ejh.14095","volume":"111","author":"MS Kurte","year":"2023","unstructured":"Kurte\u00a0MS, Siefen\u00a0AC, Jakobs\u00a0F, von Tresckow\u00a0B, Reinhardt\u00a0HC, Kron\u00a0F (2023) Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B\u2011cell lymphoma treatment options-Experience of the efficiency frontier approach. Eur J Haematol 111(6):895\u2013908","journal-title":"Eur J Haematol"},{"issue":"19","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","volume":"7","author":"A Gurumurthi","year":"2023","unstructured":"Gurumurthi\u00a0A, Westin\u00a0J, Subklewe\u00a0M (2023) The race is on: bispecifics vs CAR T\u00a0cells in B\u2011cell lymphoma. Blood Adv 7(19):5713\u20135716","journal-title":"Blood Adv"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-024-01230-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-024-01230-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-024-01230-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:54:13Z","timestamp":1765900453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-024-01230-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":24,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s00063-024-01230-z","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following statement was added: \u201cThe supplement containing this article is not sponsored by industry.\u201d","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.\u00a0Roedl, P.\u00a0Ahmadi, S.\u00a0Essmann, S.\u00a0Aamir, M.\u00a0Haar, F.\u00a0Ayuk, P.\u00a0Karagiannis and N.\u00a0Kr\u00f6ger declare that they have no competing interests. S.\u00a0Kluge received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. D.\u00a0Wichmann reports personal consultant and lecture fees from 3M, Advanz, AMEOS, Eumedica, EUSA, Gilead, Kite, Lilly, MSD, Novartis, Pfizer and Shionogi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of the Hamburg Chamber of Physicians was informed about the study (No. 2023-300294-WF). Due to the retrospective nature of the study and the deidentified study data, the need for explicit informed consent was waived. The study was in accordance with the ethical standards of the Ethics Committee of the Hamburg Chamber of Physicians on human experimentation (regional) and with the Helsinki Declaration of 1975, as most recently amended.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}